Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

PURPOSE: Metformin, widely used as antidiabetic drug, showed antitumoral effects expecially in combination with chemotherapy. Our group recently has demonstrated that metformin and gefitinib are synergistic in LKB1-wild-type NSCLC cells. In these models, metformin as single agent induced an activati...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Della Corte, Carminia Maria, Ciaramella, Vincenza, Mauro, Concetta Di, Castellone, Maria Domenica, Papaccio, Federica, Fasano, Morena, Sasso, Ferdinando Carlo, Martinelli, Erika, Troiani, Teresa, De Vita, Ferdinando, Orditura, Michele, Bianco, Roberto, Ciardiello, Fortunato, Morgillo, Floriana
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2015
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826204/
https://ncbi.nlm.nih.gov/pubmed/26673006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6559
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料